Ana María Bajo Chueca-rekin lankidetzan egindako argitalpenak (10)

2024

  1. Induction of more aggressive tumoral phenotypes in LNCaP and PC3 cells by serum exosomes from prostate cancer patients.

    e-cienciaDatos

2023

  1. Induction of more aggressive tumoral phenotypes in LNCaP and PC3 cells by serum exosomes from prostate cancer patients

    International Journal of Cancer, Vol. 153, Núm. 10, pp. 1829-1841

2016

  1. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

    Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206

2014

  1. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models

    Investigational New Drugs, Vol. 32, Núm. 5, pp. 871-882

2013

  1. Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

    Cancer Letters, Vol. 336, Núm. 1, pp. 196-203

  2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer

    International Journal of Cancer, Vol. 132, Núm. 4, pp. 755-765

2012

  1. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

    Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101

2010

  1. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer

    Peptides, Vol. 31, Núm. 11, pp. 2035-2045

  2. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

    Cancer Letters, Vol. 299, Núm. 1, pp. 11-21

2009

  1. Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398

    Peptides, Vol. 30, Núm. 12, pp. 2357-2364